Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines

• Published in: Tumori 2018-10, Vol.104 (5), p.394-400
• Main Authors: Pedretti, Sara, Urpis, Mauro, Leali, Carla, Borghetti, Paolo, Baushi, Liliana, Sala, Raffaella, Tucci, Alessandra, Greco, Diana, Pasinetti, Nadia, Triggiani, Luca, Rossi, Giuseppe, Calzavara-Pinton, Piergiacomo, Magrini, Stefano Maria, Buglione, Michela
• Format: Article
• Language: English
• ISSN: 0300-8916; 2038-2529
• DOI: 10.5301/tj.5000606

Purpose: To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy. Methods: From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Clinical and therapeutic characteristics (age, sex, histology, primary treatment and radiotherapy modality) were related to response to treatment, survival and toxicity. Results: CBCLs were divided into 4 subgroups: marginal-zone lymphoma (n = 20), follicle center lymphoma (n = 32), diffuse large-cell lymphoma (DLBCL; n = 22) and DLBCL-leg type (n = 12). No significant correlation was found between doses and systemic treatments, extent of biopsy and number of lesions. DLBCL-leg type patients were older (p = 0.05), had disseminated disease (p = 0.034), and more frequently had local (p = 0.01) or systemic recurrence (p = 0.05). CTCLs were divided into 4 subgroups: α/β CTCL (n = 3), nasal type CTCL (n = 0), γ/δ CTCL (n = 10) and mycosis fungoides (n = 10). Longer disease-free survival was observed in patients obtaining complete remission (p